Redmile Group LLC Has $6.40 Million Stake in AC Immune SA (NASDAQ:ACIU)

Redmile Group LLC decreased its position in AC Immune SA (NASDAQ:ACIU) by 6.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,694,167 shares of the company’s stock after selling 113,537 shares during the period. Redmile Group LLC owned approximately 1.71% of AC Immune worth $6,404,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. China Universal Asset Management Co. Ltd. lifted its holdings in AC Immune by 63.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 19,021 shares of the company’s stock valued at $72,000 after buying an additional 7,400 shares during the period. Silverberg Bernstein Capital Management LLC acquired a new position in AC Immune in the second quarter valued at $40,000. Vanguard Capital Wealth Advisors acquired a new position in AC Immune in the second quarter valued at $56,000. Cubist Systematic Strategies LLC acquired a new position in AC Immune in the second quarter valued at $218,000. Finally, Renaissance Technologies LLC raised its holdings in shares of AC Immune by 26.4% during the second quarter. Renaissance Technologies LLC now owns 652,079 shares of the company’s stock valued at $2,602,000 after purchasing an additional 136,300 shares during the period. Institutional investors and hedge funds own 51.36% of the company’s stock.

AC Immune Trading Down 0.3 %

Shares of NASDAQ ACIU opened at $3.20 on Thursday. The firm’s 50-day moving average price is $3.25 and its 200-day moving average price is $3.53. AC Immune SA has a 1-year low of $2.25 and a 1-year high of $5.14. The firm has a market capitalization of $316.61 million, a P/E ratio of -6.96 and a beta of 1.26.

Analysts Set New Price Targets

Several brokerages have recently weighed in on ACIU. StockNews.com lowered shares of AC Immune from a “buy” rating to a “hold” rating in a report on Tuesday, October 1st. HC Wainwright reiterated a “buy” rating and set a $16.00 price objective on shares of AC Immune in a report on Friday, November 15th.

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.